President Donald Trump’s work to lower prescription drug costs for patients will undoubtedly be one of his most significant legacies. From the legislation he recently signed to increase transparency among pharmacy benefit managers to the historic pricing deals he has negotiated with drug manufacturers, Trump has made more progress on this issue than any of his modern predecessors.
Yet while Trump’s energetic approach to drug pricing reform is admirable, prudence remains important, particularly when it comes to the “Most Favored Nation” pricing proposals that some conservatives in Congress are misguidedly championing.
These proposals would tie U.S. drug prices to the artificially low rates set by foreign governments. In doing so, they would also import the broader healthcare policies other countries manipulate to game the system, policies that ration care and disregard human life.
WILL TRUMP’S MOST FAVORED NATION APPROACH LEAD TO LOWER DRUG PRICES?
That may sound extreme, but consider that Canada
Continue reading
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!